SCHEMBL2496669

SCHEMBL2496669

Cc1cc(C2=NOC(c3cc(Cl)cc(Cl)c3)(C(F)(F)F)C2)sc1C(=O)NCC(=O)NCC(F)(F)F

nearest known ligand 0.35

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.35
LMNA P02545 1/20 0.31
PIK3CA P42336 1/20 0.30
PIK3CG P48736 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25586455 0.95 CCR1 (0.39) CCR1
SCHEMBL2501780 0.94 CCR1 (0.38) CCR1LMNA
Lotilaner SCHEMBL16860871 0.92 CCR1 (0.33) CCR1LMNA
Lotilaner SCHEMBL2502148 0.92 CCR1 (0.33) CCR1LMNA
SCHEMBL2495760 0.92 CCR1 (0.36) CCR1
SCHEMBL23874305 0.92 CCR1 (0.33) CCR1LMNA
SCHEMBL2505425 0.92 CCR1 (0.33) CCR1LMNA
SCHEMBL2499572 0.92 CCR1 (0.35) CCR1
SCHEMBL2507276 0.90 CCR1 (0.35) CCR1
SCHEMBL2507781 0.90 CCR1 (0.35) CCR1LMNAPIK3CAPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4008329-B1 ISOXAZOLINE COMPOUNDS FOR USE IN TREATING DEMODICOSIS INTERVET INT BV (NL) 2025-06-11 EP claimed
EP-2833866-B2 SOFT CHEWABLE PHARMACEUTICAL PRODUCTS INTERVET INT BV (NL) 2024-11-27 EP claimed
EP-4430947-A1 THERAPEUTIC USE OF ISOXAZOLINE COMPOUNDS, COMPOSITION OF ISOXAZOLINE COMPOUNDS AND KIT FOR THERAPEUTIC USE Przedsiebiorstwo Wielobranzowe "Vet-Agro" Sp. Z O.O. (PL) 2024-09-18 EP claimed
EP-2833867-B2 SOLID ORAL PHARMACEUTICAL COMPOSITIONS FOR ISOXAZOLINE COMPOUNDS INTERVET INT BV (NL) 2023-05-10 EP claimed
CN-108685894-B Soft chewable pharmaceutical product 英特维特国际股份有限公司 2022-04-26 CN claimed
US-11285101-B2 Soft chewable pharmaceutical products INTERVET INC. (US) 2022-03-29 US claimed
US-20190201332-A1 Soft Chewable Pharmaceutical Products INTERVET INC. (US) 2019-07-04 US claimed
EP-3079474-B1 ANTIPARASITIC USE OF ISOXAZOLINE COMPOUNDS INTERVET INT BV (NL) 2019-07-03 EP claimed
US-20190117565-A1 Soft Chewable Pharmaceutical Product INTERVET INC. (US) 2019-04-25 US claimed
US-20190117564-A1 Soft Chewable Pharmaceutical Products INTERVET INC. (US) 2019-04-25 US claimed
US-20170266165-A1 Soft Chewable Pharmaceutical Products INTERVET INC. (US) 2017-09-21 US claimed
EP-2833867-B1 SOLID ORAL PHARMACEUTICAL COMPOSITIONS FOR ISOXAZOLINE COMPOUNDS INTERVET INT BV (NL) 2017-05-17 EP claimed
US-20170100377-A1 Solid Oral Pharmaceutical Compositions for Isoxazoline Compounds INTERVET INC. (US) 2017-04-13 US claimed
US-20150057239-A1 SOLID ORAL PHARMACEUTICAL COMPOSITIONS FOR ISOXAZOLINE COMPOUNDS INTERVET INC. 2015-02-26 US claimed
US-20150057321-A1 SOFT CHEWABLE PHARMACEUTICAL PRODUCTS INTERVET INC. 2015-02-26 US claimed
EP-2833867-A1 SOLID ORAL PHARMACEUTICAL COMPOSITIONS FOR ISOXAZOLINE COMPOUNDS Intervet International B.V. (NL) 2015-02-11 EP claimed
EP-2833866-A1 SOFT CHEWABLE PHARMACEUTICAL PRODUCTS Intervet International B.V. (NL) 2015-02-11 EP claimed
WO-2013150052-A1 SOFT CHEWABLE PHARMACEUTICAL PRODUCTS INTERVET INTERNATIONAL B.V. (NL) 2013-10-10 WO claimed
WO-2013150055-A1 SOLID ORAL PHARMACEUTICAL COMPOSITIONS FOR ISOXAZOLINE COMPOUNDS INTERVET INTERNATIONAL B.V. (NL) 2013-10-10 WO claimed
US-20110245239-A1 ORGANIC COMPOUNDS ELANCO TIERGESUNDHEIT AG (CH) 2011-10-06 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170100377-A1 Solid Oral Pharmaceutical Compositions for Isoxazoline Compounds CYP3A7, SI, CYP2A7 CCR1 3053/4885LMNA 3403/4885PIK3CA 1958/4885
US-20150057321-A1 SOFT CHEWABLE PHARMACEUTICAL PRODUCTS PAM, TAS2R46, TAS2R16 CCR1 3764/4885LMNA 1522/4885PIK3CA 3165/4885
US-11285101-B2 Soft chewable pharmaceutical products PAM, TAS2R46, TAS2R16 CCR1 3764/4885LMNA 1522/4885PIK3CA 3165/4885
US-20150057239-A1 SOLID ORAL PHARMACEUTICAL COMPOSITIONS FOR ISOXAZOLINE COMPOUNDS CYP3A7, SI, CYP2A7 CCR1 3053/4885LMNA 3403/4885PIK3CA 1958/4885
US-20190117564-A1 Soft Chewable Pharmaceutical Products PAM, TAS2R46, TAS2R16 CCR1 3764/4885LMNA 1522/4885PIK3CA 3165/4885
US-20170266165-A1 Soft Chewable Pharmaceutical Products PAM, TAS2R46, TAS2R16 CCR1 3764/4885LMNA 1522/4885PIK3CA 3165/4885
US-20190117565-A1 Soft Chewable Pharmaceutical Product PAM, TAS2R46, TAS2R16 CCR1 3686/4885LMNA 1521/4885PIK3CA 3161/4885
US-20110245239-A1 ORGANIC COMPOUNDS ACHE, VDAC1, VDAC2 CCR1 4087/4885LMNA 3796/4885PIK3CA 2062/4885
US-20190201332-A1 Soft Chewable Pharmaceutical Products PAM, TAS2R46, TAS2R16 CCR1 3764/4885LMNA 1522/4885PIK3CA 3165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.